CRBU Stock Summary and Trading Ideas (Caribou Biosciences | NASDAQ:CRBU)

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Caribou Biosciences trades on the NASDAQ stock market under the symbol CRBU.

As of December 13, 2024, CRBU stock price declined to $1.91 with 1,250,688 million shares trading.

CRBU has a beta of 3.41, meaning it tends to be more sensitive to market movements. CRBU has a correlation of 0.20 to the broad based SPY ETF.

CRBU has a market cap of $172.96 million. This is considered a Micro Cap stock.

Last quarter Caribou Biosciences reported $2 million in Revenue and -$.38 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.08.

In the last 3 years, CRBU traded as high as $17.30 and as low as $1.50.

The top ETF exchange traded funds that CRBU belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

CRBU has underperformed the market in the last year with a price return of -66.3% while the SPY ETF gained +29.9%. CRBU has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.9% and -12.8%, respectively, while the SPY returned +7.8% and +0.3%, respectively.

CRBU support price is $1.83 and resistance is $2.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRBU shares will trade within this expected range on the day.